Eupraxia Pharmaceuticals (TSX:EPRX) GF Score: 34/100 (As of Jul. 08, 2026) — 55% Above Median


TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
34 GF Score
Price C$9.48
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals GF Score?

Eupraxia Pharmaceuticals TSX:EPRX +2.16% 34 GF Score is 34 as of Jul. 08, 2026, which is 55% above its 10-year median of 22.00. GuruFocus rates TSX:EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Eupraxia Pharmaceuticals has the GF Score of 34, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 2/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 5/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Eupraxia Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Eupraxia Pharmaceuticals  (TSX:EPRX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Eupraxia Pharmaceuticals GF Score Related Terms

TSX:EPRX vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's GF Score falls into.


TSX:EPRX
34GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 34 mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a GF Score of 34 as of Jul. 08, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Eupraxia Pharmaceuticals and its competitors. This is 55% above median its historical median of 22.00. Over the past decade, Eupraxia Pharmaceuticals' GF Score has ranged from 11.00 to 44.00.
Is Eupraxia Pharmaceuticals' GF Score too high?
Eupraxia Pharmaceuticals' current GF Score of 34 is 55% above median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 44.00. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' GF Score compare to VRTX and REGN?
Eupraxia Pharmaceuticals' GF Score of 34 can be compared against companies in the Biotechnology industry. Historically, Eupraxia Pharmaceuticals' own GF Score has ranged from 11.00 to 44.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current GF Score is 34, which is 55% above median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current GF Score of 34. The current GF Score is 34, which is 55% above median its 10-year median of 22.00. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current GF Score is 34 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score

Get the complete analysis for TSX:EPRX

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.48
Price